한글목차

보체 억제제 시장 규모는 최근 비약적으로 확대하고 있습니다. 2025년 212억 6,000만 달러에서 2026년에는 276억 3,000만 달러로, CAGR 30.0%로 성장할 것으로 예상됩니다. 지난 몇 년간의 성장은 보체생물학의 발전, PNH 및 AHUS 진단 증가, 생물학적 제제의 승인 확대, 전문 의료의 확대, 면역학 연구의 활성화에 기인하는 것으로 보입니다.

보체 억제제 시장 규모는 향후 몇 년간 급격한 성장이 전망됩니다. 2030년에는 778억 6,000만 달러에 달하고, CAGR은 29.6%를 기록할 전망입니다. 예측 기간의 성장 요인으로는 희귀질환 치료 확대, 보체 연구의 발전, 맞춤의료 도입 증가, 생물학적 제제에 대한 자금 투입 확대, 진단 능력 향상 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 희귀 면역 매개 질환에서의 사용 증가, C5 억제제 도입 확대, 표적 면역 조절에 대한 관심 증가, 생물학적 제제 파이프라인의 확대, 장기 요법 사용 증가 등이 있습니다.

맞춤의료에 대한 관심이 높아짐에 따라 향후 몇 년 동안 보체 억제제 분야가 확대될 것으로 예상됩니다. 개인맞춤의료는 환자의 유전적 요인, 환경적 요인, 생활습관 등에 따라 맞춤형 치료를 통해 치료 결과의 향상과 케어의 개선을 도모하는 의료 접근법입니다. 유전체학의 발전, 바이오마커 진단의 보급, 데이터 분석 기술의 고도화, 보다 정밀하고 효과적인 치료법에 대한 수요 증가로 인해 그 채택이 확대되고 있습니다. 보체 억제제는 환자의 고유한 질병 프로파일, 유전적 구성, 보체 활성도에 따라 보체 시스템의 특정 요소를 표적으로 한다는 점에서 맞춤의료와 유사한 작용기전을 가지고 있습니다. 예를 들어, 2024년 2월 미국 비영리단체인 개인맞춤의료연합(PMC)이 발표한 바에 따르면, 미국 식품의약국(FDA)은 2023년 26건의 새로운 개인맞춤의료 품목을 승인했으며, 이는 2022년 12건에서 증가한 수치입니다. 이러한 맞춤의료에 대한 관심이 높아지면서 보체저해제 분야의 성장을 견인하고 있습니다.

보체 억제제 분야에서 활동하는 주요 기업들은 C5를 표적으로 하는 보체 억제 요법과 같은 단클론항체 개발에 주력하고 있으며, 이를 통해 말단 보체의 조절을 개선하고 발작성 야간 혈색소뇨증(PNH) 환자의 용혈에 대한 지속적인 보호를 제공하는 것을 목표로 하고 있습니다. C5 표적 보체 억제 요법은 보체 단백질 C5를 특이적으로 억제하여 활성화 및 C5a, C5b로 분해되는 것을 방지하는 치료법입니다. 예를 들어, 2024년 8월 스위스에 본사를 둔 제약사 F. Hoffmann-La Roche AG는 발작성 야간 혈색소뇨증(PNH) 성인 및 청소년 환자를 대상으로 C5 억제제를 처음 투여하는 환자 또는 이전에 투여한 경험이 있는 환자를 위한 피어스카이(성분명 : 클로바리무맙)에 대해 유럽위원회(European Commission)의 승인을 획득하였습니다. 피어스카이(클로바리맙)는 보체 단백질 C5를 표적으로 하는 단클론항체로, C5의 절단을 차단하여 막 공격 복합체(MAC)의 형성을 막는 역할을 합니다. 이를 통해 보체 말단 경로를 통한 혈관 내 용혈을 억제합니다. 피어스카이는 용혈을 감소시킴으로써 헤모글로빈 수치 개선, 수혈 필요성 감소, 피로감, 빈혈 등의 증상 완화에 기여하여 환자의 삶의 질(QOL) 향상에 기여합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Complement inhibitors are therapeutic agents developed to modulate or block the activity of the complement system, a key part of the immune system involved in inflammation, pathogen clearance, and cell lysis. These inhibitors act on specific complement components, such as complement component 3 (C3) or complement component 5 (C5), to prevent excessive activation and protect tissues from damage in conditions like paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS).

The primary categories of products in the complement inhibitors sector include complement component 3 (C3) inhibitors, complement component 5 (C5) inhibitors, and complement factor D inhibitors. Complement Component 3 (C3) inhibitors are a group of therapeutic agents designed to prevent the activation of C3, a key protein in the complement cascade. The mechanisms of action for complement inhibitors encompass alternative pathway inhibitors, classical pathway inhibitors, and lectin pathway inhibitors. These treatments target various conditions such as atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (GMG), and paroxysmal nocturnal hemoglobinuria (PNH). They are delivered via intravenous (IV) and subcutaneous (SC) methods, accommodating a wide range of patient groups, including adults, geriatrics, and pediatrics.

Tariffs have raised the cost of biologic manufacturing inputs, cell culture media, and cold chain logistics used in the production of C3 and C5 inhibitor therapies. The impact is most visible in advanced complement inhibitor segments, where process complexity and supply reliability are critical. Regions such as North America and Europe have experienced higher input costs due to dependence on global biologics supply chains. Rising tariff related expenses have influenced production economics, pricing strategies, and capacity planning. Tariffs have encouraged regional biologics manufacturing, expanded local production capabilities, and strengthened biopharmaceutical supply chains over the long term.

The complement inhibitors market research report is one of a series of new reports from The Business Research Company that provides complement inhibitors market statistics, including complement inhibitors industry global market size, regional shares, competitors with a complement inhibitors market share, detailed complement inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the complement inhibitors industry. This complement inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The complement inhibitors market size has grown exponentially in recent years. It will grow from $21.26 billion in 2025 to $27.63 billion in 2026 at a compound annual growth rate (CAGR) of 30.0%. The growth in the historic period can be attributed to advances in complement biology, rising pnh and ahus diagnosis, biologics approval growth, expansion of specialty care, increased immunology research.

The complement inhibitors market size is expected to see exponential growth in the next few years. It will grow to $77.86 billion in 2030 at a compound annual growth rate (CAGR) of 29.6%. The growth in the forecast period can be attributed to growth in rare disease treatments, expanding complement research, rising personalized medicine adoption, increasing biologics funding, improved diagnostic capabilities. Major trends in the forecast period include rising use in rare immune-mediated disorders, increasing adoption of c5 inhibitors, growing focus on targeted immune regulation, expansion of biologic drug pipelines, increased long-term therapy utilization.

The increasing emphasis on personalized medicine is anticipated to drive the expansion of the complement inhibitors sector in the coming years. Personalized medicine focuses on customizing treatments for individual patients based on their genetic, environmental, and lifestyle factors to enhance outcomes and improve care. Its adoption is rising due to advancements in genomics, wider availability of biomarker-based diagnostics, enhanced data analytics technologies, and growing demand for more precise and effective therapies. Complement inhibitors operate in a similar manner to personalized medicine by targeting specific elements of the complement system according to a patient's unique disease profile, genetic makeup, and complement activity levels. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Consequently, the rising focus on personalized medicine is fueling the growth of the complement inhibitors sector.

Major companies operating in the complement inhibitors sector are concentrating on developing monoclonal antibodies, such as C5-targeted complement inhibition therapies, to improve terminal complement regulation and provide sustained protection against haemolysis in patients with paroxysmal nocturnal haemoglobinuria (PNH). C5-targeted complement inhibition therapy is a treatment approach that specifically blocks the complement protein C5 to prevent its activation and subsequent cleavage into C5a and C5b. For example, in August 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, obtained approval from the European Commission for PiaSky (crovalimab) for adults and adolescents with paroxysmal nocturnal haemoglobinuria (PNH) who are either new to or previously treated with C5 inhibitors. PiaSky (crovalimab) is a monoclonal antibody that targets complement protein C5 to stop its cleavage, thereby preventing the formation of the membrane attack complex (MAC). This inhibits terminal complement-mediated intravascular haemolysis. By reducing hemolysis, PiaSky helps improve hemoglobin levels, lowers the need for blood transfusions, and alleviates symptoms such as fatigue and anemia, enhancing patients' quality of life.

In September 2023, Magenta Therapeutics Inc., a US-based clinical-stage biotechnology company, merged with Dianthus Therapeutics Inc. for an undisclosed sum. The merged entity will concentrate on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, which is currently in a Phase I clinical trial. Dianthus Therapeutics Inc. is a US-based clinical-stage biotechnology company dedicated to developing next-generation antibody complement therapeutics for severe autoimmune diseases.

Major companies operating in the complement inhibitors market are F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Behring, UCB S.A., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., BioCryst Pharmaceuticals Inc., Pharming Group N.V., Apellis Pharmaceuticals Inc., Omeros Corporation, Akari Therapeutics Plc, InflaRx N.V., Kira Pharmaceuticals

North America was the largest region in the complement inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complement inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the complement inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complement inhibitors market consists of sales of small molecule inhibitors, recombinant proteins and biologics designed to regulate the complement system and treat complement-mediated diseases. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Complement Inhibitors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses complement inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for complement inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The complement inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Complement Component 3 (C3) Inhibitors; Complement Component 5 (C5) Inhibitors; Complement Factor D Inhibitors
• 2) By Mechanism Of Action: Alternative Pathway Inhibitors; Classic Pathway Inhibitors; Lectin Pathway Inhibitors
• 3) By Indication: Atypical Hemolytic Uremic Syndrome (aHUS); Generalized Myasthenia Gravis (gMG); Paroxysmal Nocturnal Hemoglobinuria (PNH)
• 4) By Route Of Administration: Intravenous (IV); Subcutaneous (SC)
• 5) By Patient Demographics: Adult; Geriatric; Pediatric
• Subsegments:
• 1) By Complement Component 3 (C3) Inhibitors: Small Molecule C3 Inhibitors; Monoclonal Antibody C3 Inhibitors; Peptide-Based C3 Inhibitors
• 2) By Complement Component 5 (C5) Inhibitors: Monoclonal Antibody C5 Inhibitors; Small Molecule C5 Inhibitors; RNA-Based C5 Inhibitors
• 3) By Complement Factor D Inhibitors: Small Molecule Factor D Inhibitors; Monoclonal Antibody Factor D Inhibitors
• Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Sanofi S.A.; AstraZeneca plc; Novartis AG; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; CSL Behring; UCB S.A.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals Inc.; Innovent Biologics Inc.; BioCryst Pharmaceuticals Inc.; Pharming Group N.V.; Apellis Pharmaceuticals Inc.; Omeros Corporation; Akari Therapeutics Plc; InflaRx N.V.; Kira Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Complement Inhibitors Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Complement Inhibitors Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Complement Inhibitors Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Complement Inhibitors Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Use In Rare Immune-Mediated Disorders
  • 4.2.2 Increasing Adoption Of C5 Inhibitors
  • 4.2.3 Growing Focus On Targeted Immune Regulation
  • 4.2.4 Expansion Of Biologic Drug Pipelines
  • 4.2.5 Increased Long-Term Therapy Utilization

5. Complement Inhibitors Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Hematology Centers
• 5.4 Immunology Centers
• 5.5 Research Institutions

6. Complement Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Complement Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Complement Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Complement Inhibitors Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Complement Inhibitors Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Complement Inhibitors Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Complement Inhibitors Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Complement Inhibitors Market Segmentation

• 9.1. Global Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Complement Component 3 (C3) Inhibitors, Complement Component 5 (C5) Inhibitors, Complement Factor D Inhibitors
• 9.2. Global Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Alternative Pathway Inhibitors, Classic Pathway Inhibitors, Lectin Pathway Inhibitors
• 9.3. Global Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Paroxysmal Nocturnal Hemoglobinuria (PNH)
• 9.4. Global Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous (IV), Subcutaneous (SC)
• 9.5. Global Complement Inhibitors Market, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adult, Geriatric, Pediatric
• 9.6. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Component 3 (C3) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule C3 Inhibitors, Monoclonal Antibody C3 Inhibitors, Peptide-Based C3 Inhibitors
• 9.7. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Component 5 (C5) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibody C5 Inhibitors, Small Molecule C5 Inhibitors, RNA-Based C5 Inhibitors
• 9.8. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Factor D Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule Factor D Inhibitors, Monoclonal Antibody Factor D Inhibitors

10. Complement Inhibitors Market Regional And Country Analysis

• 10.1. Global Complement Inhibitors Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Complement Inhibitors Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Complement Inhibitors Market

• 11.1. Asia-Pacific Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Complement Inhibitors Market

• 12.1. China Complement Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Complement Inhibitors Market

• 13.1. India Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Complement Inhibitors Market

• 14.1. Japan Complement Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Complement Inhibitors Market

• 15.1. Australia Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Complement Inhibitors Market

• 16.1. Indonesia Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Complement Inhibitors Market

• 17.1. South Korea Complement Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Complement Inhibitors Market

• 18.1. Taiwan Complement Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Complement Inhibitors Market

• 19.1. South East Asia Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Complement Inhibitors Market

• 20.1. Western Europe Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Complement Inhibitors Market

• 21.1. UK Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Complement Inhibitors Market

• 22.1. Germany Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Complement Inhibitors Market

• 23.1. France Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Complement Inhibitors Market

• 24.1. Italy Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Complement Inhibitors Market

• 25.1. Spain Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Complement Inhibitors Market

• 26.1. Eastern Europe Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Complement Inhibitors Market

• 27.1. Russia Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Complement Inhibitors Market

• 28.1. North America Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Complement Inhibitors Market

• 29.1. USA Complement Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Complement Inhibitors Market

• 30.1. Canada Complement Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Complement Inhibitors Market

• 31.1. South America Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Complement Inhibitors Market

• 32.1. Brazil Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Complement Inhibitors Market

• 33.1. Middle East Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Complement Inhibitors Market

• 34.1. Africa Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Complement Inhibitors Market, Segmentation By Product Type, Segmentation By Mechanism Of Action, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Complement Inhibitors Market Regulatory and Investment Landscape

36. Complement Inhibitors Market Competitive Landscape And Company Profiles

• 36.1. Complement Inhibitors Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Complement Inhibitors Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Complement Inhibitors Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Complement Inhibitors Market Other Major And Innovative Companies

• Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Behring, UCB S.A., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., BioCryst Pharmaceuticals Inc., Pharming Group N.V., Apellis Pharmaceuticals Inc., Omeros Corporation, Akari Therapeutics Plc, InflaRx N.V., Kira Pharmaceuticals

38. Global Complement Inhibitors Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Complement Inhibitors Market

40. Complement Inhibitors Market High Potential Countries, Segments and Strategies

• 40.1 Complement Inhibitors Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Complement Inhibitors Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Complement Inhibitors Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer